Aβ1-40 and Aβ1-42 levels in the CSF, TEMT has affected most major AD markers in the CSF and/or plasma (e.g., p-tau, t-tau, oligomeric Aβ, CRP, and cytokines), an attribute that few, if any, AD therapeutics in clinical trials can claim. This evidence concerns the gene MAPT and Alzheimer disease.